These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30117055)

  • 1. Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios.
    Gomez-Peralta F; Abreu C; Gomez-Rodriguez S; Barranco RJ; Umpierrez GE
    Diabetes Ther; 2018 Oct; 9(5):1775-1789. PubMed ID: 30117055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials.
    Ling J; Cheng P; Ge L; Zhang DH; Shi AC; Tian JH; Chen YJ; Li XX; Zhang JY; Yang KH
    Acta Diabetol; 2019 Mar; 56(3):249-272. PubMed ID: 30242726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial.
    Umpierrez GE; Cardona S; Chachkhiani D; Fayfman M; Saiyed S; Wang H; Vellanki P; Haw JS; Olson DE; Pasquel FJ; Johnson TM
    J Am Med Dir Assoc; 2018 May; 19(5):399-404.e3. PubMed ID: 29289540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPP4 Inhibitors in the Management of Hospitalized Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Rabizadeh S; Tavakoli Ardakani MA; Mouodi M; Bitaraf M; Shab-Bidar S; Esteghamati A; Nakhjavani M
    Adv Ther; 2020 Sep; 37(9):3660-3675. PubMed ID: 32671686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
    Hollander PA; Kushner P
    Postgrad Med; 2010 May; 122(3):71-80. PubMed ID: 20463416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal-Bolus Insulin Regimen: A Prospective Randomized Study.
    Batule S; Ramos A; Pérez-Montes de Oca A; Fuentes N; Martínez S; Raga J; Pena X; Tural C; Muñoz P; Soldevila B; Alonso N; Umpierrez G; Puig-Domingo M
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35628938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment.
    Janardhan S; Sastry GN
    Curr Drug Targets; 2014 Jun; 15(6):600-21. PubMed ID: 24611684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.
    Detournay B; Halimi S; Robert J; Deschaseaux C; Dejager S
    Vasc Health Risk Manag; 2015; 11():417-25. PubMed ID: 26229480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study.
    Pérez-Belmonte LM; Osuna-Sánchez J; Millán-Gómez M; López-Carmona MD; Gómez-Doblas JJ; Cobos-Palacios L; Sanz-Cánovas J; Barbancho MA; Lara JP; Jiménez-Navarro M; Bernal-López MR; Gómez-Huelgas R
    Ann Med; 2019; 51(3-4):252-261. PubMed ID: 31037970
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ
    Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues.
    Gautier JF; Monguillon P; Verier-Mine O; Valensi P; Fiquet B; Dejager S; Charbonnel B
    Diabetes Res Clin Pract; 2016 Jun; 116():26-8. PubMed ID: 27321312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies.
    Son JW; Kim S
    Diabetes Metab J; 2015 Oct; 39(5):373-83. PubMed ID: 26566494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
    Wang N; Yang T; Li J; Zhang X
    Diabetes Metab Syndr Obes; 2019; 12():1513-1526. PubMed ID: 31692532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Neumiller JJ; Campbell RK
    Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.